Isoket 1 mg/ml concentrate for solution for injection or infusion

Each ml contains 1 mg of isosorbide dinitrate.

Each 10 ml ampoule contains 10 mg of isosorbide dinitrate.

Each 50 ml bottle contains 50 mg of isosorbide dinitrate.

Each 100 ml contains 100 mg of isosorbide dinitrate.

Excipients:

Each ml contains 3.54 mg (0.154 mmol) sodium (as sodium chloride).

Each 10 ml ampoule contains 35.4 mg (1.54 mmol) sodium (as sodium chloride).

Each 50 ml bottle contains 177 mg (7.70 mmol) sodium (as sodium chloride).

Each 100 ml bottle contains 354 mg (15.4 mmol) sodium (as sodium chloride).

For a full list of excipients, see section 6.1.

Concentrate for solution for injection or infusion (sterile concentrate).

Clear, colourless solution.

1. Intravenous

Isoket is indicated in the treatment of unresponsive left ventricular failure secondary to acute myocardial infarction, unresponsive left ventricular failure of various aetiology and severe or unstable angina pectoris.

2. Intra-coronary

Isoket is indicated during percutaneous transluminal coronary angioplasty to facilitate prolongation of balloon inflation and to prevent or relieve coronary spasm.

Dosage: Adults, including the elderly

Intravenous route

A dose of between 2 mg and 12 mg per hour is usually satisfactory. However, dosages up to 20 mg per hour administered should be adjusted to the patient response.

Intra-coronary Route

The usual dose is 1 mg given as a bolus injection prior to balloon inflation. Further doses maybe given not exceeding 5 mg within a 30 minute period.

Children

The safety and efficacy of Isoket has not yet been established in children.

Administration:

Isoket is a concentrated solution and must be diluted prior use. The diluted solution should never be injected directly in the form of a bolus except via the intra-coronary route prior to balloon inflation. A dilution of 50% is advocated for intracoronary administration.

Isoket can be administered as an intravenous admixture with a suitable vehicle, see section 6.6.

Prepared Isoket admixtures should be given by intravenous infusion or with the aid of a syringe pump incorporating a glass or rigid plastic syringe. During administration the patient's blood pressure and pulse should be closely monitored.

These are common to all nitrates: hypersensitivity to isosorbide dinitrate, other nitrates or any of the excipients, marked anaemia, cerebral haemorrhage, head trauma, diseases associated with an increased intracranial pressure, hypovolaemia, severe hypotension (systolic blood pressure less than 90mmHg), aortic and/or mitral valve stenosis, closed angle glaucoma.

Use in circulatory collapse or low filling pressure is also contraindicated.

Isoket should not be used in the treatment of cardiogenic shock (unless some means of maintaining an adequate diastolic pressure is undertaken), hypertrophic obstructive cardiomyopathy, constrictive pericarditis or cardiac tamponade.

Phosphodiesterase type-5 inhibitors (e.g. sildenafil, tadalafil and vardenafil) have been shown to potentiate the hypotensive effects of nitrates. Therefore, Isoket must not be given to patients receiving phosphodiesterase-5 inhibitors (see section 4.5).

Isoket should be used with caution and under medical supervision in patients who are suffering from

• hypothyroidism,

• malnutrition,

• severe liver or renal disease

• hypothermia

• orthostatic syndrome

The development of tolerance (decrease in efficacy) as well as cross tolerance towards other nitrate-type drugs (decrease in effect in case of a prior therapy with another nitrate drug) has been described. For a decrease in, or loss of, effect to be prevented, continuously high dosages must be avoided.

Blood pressure and pulse rate should always be monitored and the dose adjusted according to the patient's response.

Isoket contains 0.15mmol (3.54mg) of sodium per ml and should be taken into consideration by patients on a controlled sodium diet.

Concurrent intake of drugs with blood pressure lowering properties e.g. beta-blockers, calcium antagonists, vasodilators etc. and /or alcohol may potentiate the hypotensive effect of Isoket. This might also occur with neuroleptics and tricyclic antidepressants.

Also phosphodiesterase-5 inhibitors e.g. sildenafil, potentiate the hypotensive effects of Isoket. This might lead to life-threatening cardiovascular complications, see section 4.3.

Reports suggest that, when administered concomitantly, Isoket may increase the blood level of dihydroergotamine and its hypertensive effect.

No data have been reported which would indicate the possibility of adverse effects resulting from the use of isosorbide dinitrate in pregnancy. Safety in pregnancy, however, has not been established. Isosorbide dinitrate should only be used in pregnancy and during lactation if, in the opinion of the physician, the possible benefits of treatment outweigh the possible hazards.

As for other drugs which produce changes in blood pressure, patients taking Isoket should be warned not to drive or operate machinery if they experience dizziness or related symptoms.

During administration of Isoket the following undesirable effects may be observed:

Nervous system disorders: headache, dizziness, somnolence.

Cardiac disorders: tachycardia, angina pectoris aggravated.

Vascular disorders: orthostatic hypotension, collapse (sometimes accompanied by bradyarrhythmia and syncope).

Gastrointestinal disorders: nausea, vomiting, heartburn.

Skin and subcutaneous tissue disorders: allergic skin reactions (e.g. rash), flush, angioedema, Stevens-Johnson-Syndrome, in single cases: exfoliative dermatitis.

General disorders and administration site conditions: asthenia

Severe hypotensive responses have been reported for organic nitrates including nausea, vomiting, restlessness, pallor, and excessive perspiration.

During treatment with Isoket a temporary hypoxemia may occur due to a relative redistribution of the blood flow in hypoventilated alveolar areas. Particularly in patients with coronary artery disease this may lead to a myocardial hypoxia.

Symptoms:

• Fall of blood pressure 90 mmHg

• Pallor

• Sweating

• Weak pulse

• Tachycardia

• Postural dizziness

• Headache

• Asthenia

• Dizziness

• Nausea

• Vomiting

• Diarrhoea

• Methaemoglobinaemia has been reported in patients receiving other organic nitrates. During isosorbide dinitrate biotransformation nitrite ions are released, which may induce methaemoglobinaemia and cyanosis with subsequent tachypnoea, anxiety, loss of consciousness and cardiac arrest. It cannot be excluded that an overdose of Isoket may cause this adverse reaction.

• In very high doses the intracranial pressure may be increased. This might lead to cerebral symptoms.

General procedure:

• Stop delivery of the drug

• General procedures in the event of nitrate-related hypotension:

Special procedure:

• Raise the blood pressure if the blood pressure is very low.

• Additional administration of noradrenaline or other vasoconstrictors.

• Treatment of methaemoglobinaemia

• Resuscitation measures

In case of signs of respiratory and circulatory arrest, initiate resuscitation measures immediately.

ATC Code: CO1D A08 Vasodilators used in cardiac diseases – organic nitrates.

Isosorbide dinitrate is an organic nitrate, which in common with other cardioactive nitrates, is a vasodilator. It produces decreased left and right ventricular end-diastolic pressures to a greater extent than the decrease in systemic arterial pressure, thereby reducing afterload and especially the preload of the heart.

Isosorbide dinitrate influences the oxygen supply to ischaemic myocardium by causing the redistribution of blood flow along collateral channels and from epicardial to endocardial regions by selective dilatation of large epicardial vessels.

It reduces the requirement of the myocardium for oxygen by increasing venous capacitance, causing a pooling of blood in peripheral veins, thereby reducing ventricular volume and heart wall distension.

Isosorbide dinitrate (ISDN) is eliminated from plasma with a short half-life (about 0.7h). The metabolic degradation of ISDN occurs via denitration and glucuronidation, like all organic nitrates. The rate of formation of the metabolites has been calculated for isosorbide-5-mononitrate (IS-5-MN) with 0.27 h ^-1, and isosorbide (IS) with 0.16 h^-1. IS-5-MN and IS-2-MN are the primary metabolites which are also pharmacologically active. IS-5-MN is metabolised to isosorbide 5-mononitrate-2-glucuronide (IS-5-MN-2-GLU). The half-life of this metabolite (about 2.5h) is shorter than that of IS-5-MN (about 5.1h). The half-life of ISDN is the shortest of all and that of IS-2-MN (about 3.2h) lies in between.

Acute toxicity:

Acute toxicity of isosorbide dinitrate was related to an exaggerated pharmacodynamic effect. Animal studies showed good local tolerability of the undiluted isosorbide dinitrate solution.

Chronic toxicity:

In chronic oral toxicity studies in rats and dogs, toxic effects including CNS symptoms and an increase in liver weight, were observed at exposures considered sufficiently in excess of the maximum human exposure levels indicating little relevance to clinical use.

Reproduction studies:

There is no evidence from animal studies suggesting a teratogenic effect of isosorbide dinitrate. At high maternally toxic oral doses, isosorbide dinitrate was associated with increased post-implantation loss and reduced survival of offspring.

Mutagenicity and carcinogenicity:

No evidence for mutagenic effect was found in both in vitro and in vivo tests.

A long-term study in rats did not provide any evidence for carcinogenicity.

Sodium chloride

Water for injections

Sodium hydroxide (for pH-adjustment)

Hydrochloric acid solution (for pH-adjustment)

The use of PVC giving sets and containers should be avoided since significant losses of the active ingredient by adsorption can occur.

This medicinal product must not be mixed with other medicinal products except those mentioned in 6.6.

5 years, as packaged for sale.

Admixtures are stable for approximately 24 hours at room temperature in the recommended containers.

Open ampoules or bottles should be used immediately and any unused drug discarded.

There are no special precautions for storage of the product as packaged for sale.

Ten 10 ml clear glass ampoules.

Clear, Type I glass vials sealed with a grey stopper and a red flip-off aluminium cap, containing 50ml or 100ml of concentrate and packed in a cardboard carton.

Clear, Type I glass vials sealed with a grey stopper and a red flip-off aluminium cap, containing 50ml or 100ml of concentrate and packed in a cardboard carton containing a Sterifix Minispike to aid withdrawal of the product from the bottle.

Not all pack sizes may be marketed.

Isoket contains isosorbide dinitrate in isotonic solution and is compatible with commonly employed infusion fluids, such as sodium chloride solution, dextrose solution, glucose solution, Ringer's solution and solutions containing albumin. No incompatibilities have so far been demonstrated.

Isoket is compatible with glass infusion bottles and infusion packs made from polyethylene. Isoket may be infused slowly using a syringe pump with glass or plastic syringe.

Example of admixture preparation

To obtain a dose of 6 mg per hour, add 50 ml of Isoket 1 mg/ml to 450 ml of a suitable vehicle, under aseptic conditions. The resultant admixture (500ml) contains 100 µg/ml (1mg/10ml) isosorbide dinitrate. An infusion rate of 60ml per hour (equivalent to 60 paediatric microdrops per minute or 20 standard drops per minute) will deliver the required dose of 6mg per hour.

Should it be necessary to reduce fluid intake, 100ml of Isoket 1 mg/ml may be diluted to 500ml using a suitable vehicle. The resultant solution now contains 200 µg/ml (2mg/10ml) isosorbide dinitrate. An infusion rate of 30ml per hour (equivalent to 30 paediatric microdrops per minute or 10 standard drops per minute), will deliver the required dose of 6 mg per hour.

A dilution of 50% is advocated to produce a solution containing 0.5 mg/ml where fluid intake is strictly limited.

SCHWARZ PHARMA Limited

5 Hercules Way

Leavesden Park

Watford

WD25 7GS

United Kingdom

PL 04438/0001

10 February 2002

June 2010